RTFCCR invites academic institutions and not-for-profit organizations to collaborate on innovative, patient-centered clinical trials. Our mission is to improve cancer patients’ treatment options and quality of life by funding studies focused on detection, treatment, and implementation.
We support phase I to phase III interventional clinical trials but do not fund basic research, phase IV trials, or observational studies. Funding is available to institutions worldwide where effective grant oversight is feasible.
Submission Criteria
- The interventional clinical trial can be an early—to—late—stage clinical trial (Phase 1, 2, and 3) with a patient partner involvement in the study protocol design.
- Only applications aimed at detecting and intervening in early cancer (pre-cancerous changes) can also be considered at the pre-clinical validation stage.
- Pharmaceutical agents used in the study can be generic (off-patent repurposing), registered for this indication, or under development by an academic institution.
- Clinical trials testing immunotherapies should be discussed with RTFCCR before application submission.
- Final selection will be contingent on scientific review, strategic portfolio fit, and availability of funds
Key Dates
Application deadlines: 9 March, 22 June and 23 November 2026